8-K - SBFM - Equibles

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM

8-K

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April1, 2025

SUNSHINE

BIOPHARMA INC.

(Exact name of registrant as specified in its charter)

Colorado	001-41282	20-5566275
(State or other jurisdiction<br><br> <br>of incorporation)	(Commission File Number)	(IRS Employer ID No.)

333

Las Olas Way

CU4Suite 433

Fort Lauderdale

, FL

33301

(Address of principal executive offices) (zip code)

(954) 330-0684

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class	Trading Symbol	Name of Each Exchange on Which Registered
Common Stock, par value $0.001	SBFM	The Nasdaq<br> Stock Market LLC
Common Stock Purchase Warrants	SBFMW	The Nasdaq<br> Stock Market LLC

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and FinancialCondition.

On April 1, 2025, Sunshine Biopharma Inc. (the “Company”) issued a press release announcing the Company’s financial results for the fiscal year ended December 31, 2024. The press release is attached hereto as Exhibit 99.1.

In accordance with General Instruction B.2 of Form 8-K, the information in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	Press release
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

| 2 |

| --- |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: April 2, 2025	SUNSHINE BIOPHARMA INC.
	By: /s/ Dr. Steve N. Slilaty
	Dr. Steve N. Slilaty, Chief Executive Officer

| 3 |

| --- |

Exhibit 99.1

****

SunshineBiopharma Reports Revenue of $34.9M in Fiscal 2024, Up 45% From Last Year

FORT LAUDERDALE, FL / ACCESSWIRE / April 1, 2025 / Sunshine Biopharma Inc. (NASDAQ: “SBFM”) (the “Company”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that it has filed its 2024 annual report on Form 10-K on Tuesday, April 1, 2025. The following are highlights of the report:

·	Revenue in 2024 grew to $34.9 million, a 45% increase over 2023 revenue of $24.1 million.
·	Completed an underwritten public offering of approximately $10 million in gross proceeds for expansion<br>of sales operations.
·	Launched 13 new generic prescription drugs, 4 under cross-licensing agreements and 9 under distribution<br>agreements.
·	Received regulatory approval from Health Canada for marketing of the oncology drug NIOPEG®, a biosimilar<br>of NEULASTA®.
·	Announced publication of groundbreaking research results in the Journal of Medicinal Chemistry (J. Med.<br>Chem. 2024, 67, 13681−13702) demonstrating the superior efficacy of Sunshine Biopharma’s new Coronavirus PLpro inhibitor.<br>The study showcases a PLpro inhibitor with sub-micromolar potency and robust in vivo efficacy in a mouse model of SARS-CoV-2 infection.<br>This peer-reviewed research marks an important milestone in Sunshine Biopharma's ongoing efforts to develop proprietary therapies in critical<br>disease areas.
·	Announced completion of mouse model studies providing proof-of-concept for the Company’s K1.1 mRNA<br>Lipid Nanoparticle as a novel therapeutic agent for human hepatocellular carcinoma. Human hepatocellular carcinoma is the third leading<br>cause of cancer-related deaths worldwide and the most common type of primary liver cancer in adults.

“We are pleased with our accomplishments in 2024, as we remain committed to reaching profitability in the near future,” said Dr. Steve Slilaty, CEO of the Company. “Looking ahead, we are excited about the opportunities for growth in 2025 and beyond, as we continue to advance our proprietary drug development program to deliver more life-saving medicines to the market.”

The following are key elements of the Income Statement contained in the Company’s 2024 report:

	2024		2023
Revenue	$	34,874,283	$	24,092,787
Gross Profit	$	10,669,794	$	8,339,171
General & Administrative Expenses	$	16,481,915	$	13,124,470
Net Loss	$	5,134,116	$	4,506,044

| 1 |

| --- |

About Sunshine Biopharma Inc.

Sunshine Biopharma currently has 70 generic prescription drugs on the market in Canada and 13 additional drugs scheduled to be launched in the remainder of 2025. Among the new drugs to be launched is NIOPEG®, a biosimilar of NEULASTA®. Like NEULASTA®, NIOPEG® is a long-acting form of recombinant human granulocyte colony-stimulating factor (filgrastim). It is indicated to decrease the incidence of infection in patients with non-myeloid malignancies receiving anti-neoplastic therapy. In addition, Sunshine Biopharma is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and (ii) PLpro protease inhibitor, a small molecule for treatment of SARS Coronavirus infections. For more information, please visit: www.sunshinebiopharma.com.

All registered trademarks are the property of their respective owners.

Safe Harbor Forward-Looking Statements

This press release contains forward-lookingstatements which are based on current expectations, forecasts, and assumptions of Sunshine Biopharma Inc. (the “Company”)that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated orexpected. These statements appear in this release and include all statements that are not statements of historical fact regarding theintent, belief or current expectations of the Company, including statements related to the Company’s drug development activities,financial performance, and future growth. These risks and uncertainties are further described in filings and reports by the Company withthe U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from thoseprojected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in the Company’sfilings with the SEC. Reference is hereby made to cautionary statements and risk factors set forth in the Company’s most recentSEC filings.

For more information, please contact:

Camille Sebaaly, CFO

Direct Line: 514-814-0464

camille.sebaaly@sunshinebiopharma.com

| 2 |

| --- |